One of the encouraging signs during the depths of the financial crisis was the then 3%+ dividend yield on the S&P 500.  It was a welcome relief for those seeking out yield and in sharp contrast to the record of the prior decade.  Unfortunately that attractive yield has disappeared as the market has rallied.  One sector that continues to provide attractive yields is the pharmaceutical sector.  The large pharmaceutical names have transitioned from growth darlings to yield plays.  During this transition their stock prices have become hostage to high dividends.  That cash could be used to fund additional research, etc.  In today’s screencast we look at the dividend trap big pharma may have laid for itself.

Items mentioned in the above screencast:

Don’t look now, but dividend yields are now well below 2.0%.  (ROI)

Morningstar’s ultimate stock pickers love pharmaceutical stocks.  (Morningstar)

Eli Lilly’s dividend yield over time.  (YCharts)

Has Eli Lilly fallen into a high dividend trap?  (WSJ)

A daily price chart of Eli Lilly (LLY).  (Finviz)

This content, which contains security-related opinions and/or information, is provided for informational purposes only and should not be relied upon in any manner as professional advice, or an endorsement of any practices, products or services. There can be no guarantees or assurances that the views expressed here will be applicable for any particular facts or circumstances, and should not be relied upon in any manner. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment.

The commentary in this “post” (including any related blog, podcasts, videos, and social media) reflects the personal opinions, viewpoints, and analyses of the Ritholtz Wealth Management employees providing such comments, and should not be regarded the views of Ritholtz Wealth Management LLC. or its respective affiliates or as a description of advisory services provided by Ritholtz Wealth Management or performance returns of any Ritholtz Wealth Management Investments client.

References to any securities or digital assets, or performance data, are for illustrative purposes only and do not constitute an investment recommendation or offer to provide investment advisory services. Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others.

Please see disclosures here.

Please see the Terms & Conditions page for a full disclaimer.